Gefitinib Mylan is a cancer medicine used to treat adults who have non-small cell lung cancer that is locally advanced or metastatic (when cancer cells have spread from the original site to other parts of the body). It is used in patients whose cancer cells have a mutation in the genes that make a protein called epidermal growth factor receptor (EGFR). Gefitinib Mylan contains the active substance gefitinib and is a ‘generic medicine’. This means that Gefitinib Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Iressa.
Therapeutic Indication
### Therapeutic indication Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non?small cell lung cancer (NSCLC) with activating mutations of EGFR?TK.
Therapeutic Area (MeSH)
ATC Code
L01XE02
ATC Item
xl 01 xe 02
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| gefitinib | N/A | 吉非替尼 |
EMA Name
Gefitinib Mylan
Medicine Name
Gefitinib Mylan
Aliases
N/ANo risk management plan link.
